Pharma Extends Crucial Support to Indices Amidst Broader Market Downturn, This Pharma Major Scaled Up 2.12 Per Cent

The company Receives Establishment Inspection Report (EIR) from the U.S. FDA for Its Manufacturing Facility in Somerset, New Jersey

After the weekend break, the Indian equity market resumed trading on a weak note, with market bleeding continuing. The benchmark NIFTY 50 slipped to the day’s low of 22,548 points. Pharma stocks provided much-needed support to the broader market, with the Nifty Pharma Index reaching a high of 20,550.6 points, up 1.45 per cent from the opening levels.

Lupin Ltd, a major pharmaceutical company, remained in focus on Monday, February 24, 2025, as its stock surged to a day’s high of Rs 1,945, marking a gain of over 2.12 per cent following a key regulatory development. Lupin Limited announced in a press release that it has received the Establishment Inspection Report (EIR) from the U.S. FDA for its manufacturing facility in Somerset, New Jersey. The inspection was conducted between January 27 and January 31, 2025. Nilesh Gupta, Managing Director of Lupin, highlighted that this milestone reinforces the company’s commitment to maintaining high standards of quality and regulatory compliance, further strengthening its position as a leading pharmaceutical manufacturer.

DSIJ's 'Large Rhino' service recommends blue chip stocks of Large Cap companies that have leadership positions in their category. If this interests you, do download the service details here.

Lupin Limited is a global pharmaceutical company headquartered in Mumbai, India, with its products available in over 100 markets worldwide. The company specializes in a range of pharmaceutical offerings, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Lupin has a strong presence in both India and the U.S., focusing on therapy areas such as respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. The company operates 15 manufacturing facilities and seven research centers globally, supported by a workforce of over 23,000 professionals. Lupin is also engaged in related ventures through its subsidiaries: Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions. It has a market capitalization exceeding Rs 87,571 crore. Over the past year, its stock has risen by 19 per cent, significantly outperforming the NIFTY 50’s return of 1.92 per cent over the same period.

Disclaimer: This article is for informational purposes only and should not be construed as investment advice.